Project Grant HT94252510543
Award Date
6/15/25
Completion Date
6/14/28
Dollars Obligated
$963K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tempe, AZ 85281, USA
Similar Awards
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
Arizona State University received a $1,876,224 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The grant will fund research from July 1, 2022 to September 30, 2024 to identify immunogenic epitopes for Lyme disease using machine learning-based comprehensive reactivity profiling of patients' antibodies. The Military Medical Research and Development program supports biomedical research with the goals of...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
This federal Project Grant award of $1,117,328.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research on proteomic biomarkers for amyotrophic lateral sclerosis (ALS) disease prognosis and progression monitoring. The award recipient, The University of Queensland in Australia, will conduct this research project from April 1, 2025, through March 31, 2027. The project aims to develop innovative...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
This $1,078,882 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to develop a chemical engineering approach for addressing amyotrophic lateral sclerosis (ALS). The research aims to gain a more sophisticated understanding of the multimodal therapeutic actions of donor and host neural stem cells in ALS. This 2-year...
The University of Miami was awarded a $894,330.00 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "TARGETING AXONAL REGENERATION PATHWAYS AS A THERAPEUTIC APPROACH TO ALS", will support advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The award period is from February 1, 2025 to January...
The Department of the Army Medical Command awarded Arizona State University a $722,815 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research from September 2022 through September 2026 aimed at preventing suicide among survivors of military sexual violence. The grant funding will support ASU's efforts to identify critical risk periods and factors that attenuate and exacerbate suicide risk for this population in order to inform prevention...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The Department of the Army Medical Command, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,210,500 project grant to Mayo Clinic to explore novel biomarkers for amyotrophic lateral sclerosis (ALS) using a multiomics approach. The 3-year project (Apr 2025 - Mar 2028) will utilize immunoprofiling, extracellular vesicle analysis, and TDP-43 aggregation assays to identify potential diagnostic and prognostic markers for ALS. Mayo Clinic, a renowned non-profit...